Available Technologies
# of Displayed Technologies: 10 / 10
Applied Category Filter (Click To Remove): Vaccines
Revolutionizing Cancer Immunotherapy with Novel Chimeric B-cell Epitope Peptide Vaccines
TS-065697 — Chimeric B-cell epitope peptide vaccines targeting human PD-L1 and/or CTLA-4 to induce immune response against the PD-1/PD-L1 signaling pathway.
The emergence of immune checkpoint inhibitors revolutionized cancer immunotherapy. Monoclonal antibodies targeting PD-1, PD-L1 and CTLA-4 have shown impressive clinical outcomes.
The Need
Despite their effectiveness, current monoclonal antibody treatments have limitations such as low response ra…
- College: College of Medicine (COM)
- Inventors: Kaumaya, Pravin
- Licensing Officer: Willson, Christopher
Introducing HexaPro VSV: A Breakthrough in COVID-19 Vaccine Technology
TS-064191 —
The emergence of SARS-CoV-2 variants poses a significant challenge to existing COVID-19 vaccines, necessitating the development of a more durable and broadly protective solution. Current vaccines show reduced efficacy over time and struggle against Variants of Concern (VoCs) such as Omicron. Addre…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Chamblee, Michelle; Lu, Mijia; Zhang, Yuexiu
- Licensing Officer: Willson, Christopher
A next generation intranasal trivalent Measles, Mumps and Covid vaccine
TS-064189 — The Need
The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Xu, Jiayu; Zhang, Yuexiu
- Licensing Officer: Willson, Christopher
Live Attenuated Mumps Virus-Based SARS-CoV-2 Vaccines for Infants and Children
TS-062231 — The Need: Addressing the Urgent Need for a Safe and Effective SARS-CoV-2 Vaccine for Infants and Children
The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought about significant economic, emotional, and public health challenges worldwide. The pressing dema…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Boyaka, Prosper; Lu, Mijia; Zhang, Yuexiu
- Licensing Officer: Willson, Christopher
Novel method for attenuating live vaccine candidates for non-segmented negative-sense RNA viruses
TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease
Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; He, Chuan; Lu, Mijia; Niewiesk, Stefan; Peeples, Mark; Xue, Miaoge; Zhang, Zijie; Zhao, Boxuan
- Licensing Officer: Willson, Christopher
Development of a live attenuated vaccine for leishmaniasis using CRISPR technology
TS-051167 — Methods of production and use of modified Leishmania species and compositions of live, attenuated organisms, immunogenic compositions, vaccines, and pharmaceutical compositions.
Leishmaniasis is a neglected tropical disease caused by infection with protozoans of the 15 genus Leishmania that is transmitted by infected sand flies. Worldwide, an estimated 1 billion people are at risk of infection in tropical and subtropical countries, with up to 1.7 million new cases in 98 c…
- College: College of Medicine (COM)
- Inventors: Satoskar, Abhay
- Licensing Officer: Willson, Christopher
Novel Immunomodulators and Vaccine Adjuvants
TS-038032 — A class of compounds possessing potent immunomodulatory activity, to enhance the protection of vaccines against infectious agents.
While vaccines are commonly used today for a variety of diseases and have proven efficacious for disease prevention, some vaccines do not efficiently activate an immune response. About 10% of vaccinations fail to mount adequate antibody levels to routine vaccinations. Also, many viruses rapidly mu…
- College: College of Medicine (COM)
- Inventors: Satoskar, Abhay; Ainslie, Kristy; Bachelder, Eric; Fuchs, James; Kinghorn, Alan "Dr. A. Douglas Kinghorn"; Parinandi, Narasimham
- Licensing Officer: Willson, Christopher
Novel Live Attenuated Vaccines for Pneumoviruses
TS-037753 — A method to create vaccines for pneumoviruses, using recombinant viruses.
The Need
Pneumoviruses consist of pathogens that target the upper respiratory tract within their specific hosts. These include many important human and animal pathogens, such as human respiratory syncytial virus (hRSV), hMPV, bovine RSV, pneumonia virus of mice (PVM), and avian metapneumovirus (aMP…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Cai, Hui; Peeples, Mark; Wang, Rongzhang
- Licensing Officer: Willson, Christopher
Novel Vaccine for Respiratory Syncytial Virus
TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.
The Need: Respiratory Syncytial Virus (RSV) is a major cause of infant hospitalization due to acute lower respiratory tract infections (ALRI) in children under 5 years of age globally, causing up to 200,000 deaths annually. RSV leads to significantly more hospitalizations than influenza in children …
- College: College of Veterinary Medicine
- Inventors: Niewiesk, Stefan; Binjawadagi, Basavaraj; Li, Jianrong; Peeples, Mark
- Licensing Officer: Willson, Christopher
Improved Mucosal Immune Response During Vaccination
TS-015239 — Enhancing the mucosal (IgA) immune response by transiently blocking a specific cellular subset during vaccination.
The Need: Enhancing Mucosal Immune Response for Effective Vaccination
Infectious agents primarily invade the body through mucosal tissues, necessitating a robust immune response at these vulnerable sites. However, conventional vaccines often fail to induce sufficient immunoglobulin-A (IgA) antibodi…
- College: College of Veterinary Medicine
- Inventors: Boyaka, Prosper
- Licensing Officer: Willson, Christopher
